TY - JOUR
T1 - IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment
AU - Leone, Amanda
AU - Picker, Louis J.
AU - Sodora, Donald L.
PY - 2009
Y1 - 2009
N2 - While highly active antiretroviral therapy (HAART) regimens have proven to be effective in controlling active HIV replication, complete recovery of CD4+ T cells does not always occur, even among patients with high level virologic control. Recent advances in understanding the biology of T cell production and homeostasis have created the potential to augment anti-viral therapies with immunotherapies designed to facilitate recovery of the HIV-damaged immune system, in particular, the recovery of CD4+ T cell populations. The common gamma-chain cytokines IIL-2, IL-7 and IL-15 are primary regulators of T cell homeostasis and thus have been considered prime candidate immunotherapeutics, both for increasing T cell levels/function and for augmenting vaccine-elicited viral-specific T cell responses. Recent studies have established that these cytokines have distinct functional roles in immune homeostasis, which focus on specific T cell populations. The ability of these cytokines to provide immunotherapeutic benefit to HIV+ patients will depend on their ability to stably increase or functionally enhance the desired T cell target population without adverse virologic or clinical consequences.
AB - While highly active antiretroviral therapy (HAART) regimens have proven to be effective in controlling active HIV replication, complete recovery of CD4+ T cells does not always occur, even among patients with high level virologic control. Recent advances in understanding the biology of T cell production and homeostasis have created the potential to augment anti-viral therapies with immunotherapies designed to facilitate recovery of the HIV-damaged immune system, in particular, the recovery of CD4+ T cell populations. The common gamma-chain cytokines IIL-2, IL-7 and IL-15 are primary regulators of T cell homeostasis and thus have been considered prime candidate immunotherapeutics, both for increasing T cell levels/function and for augmenting vaccine-elicited viral-specific T cell responses. Recent studies have established that these cytokines have distinct functional roles in immune homeostasis, which focus on specific T cell populations. The ability of these cytokines to provide immunotherapeutic benefit to HIV+ patients will depend on their ability to stably increase or functionally enhance the desired T cell target population without adverse virologic or clinical consequences.
UR - http://www.scopus.com/inward/record.url?scp=59649116097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59649116097&partnerID=8YFLogxK
U2 - 10.2174/157016209787048519
DO - 10.2174/157016209787048519
M3 - Review article
C2 - 19149557
AN - SCOPUS:59649116097
SN - 1570-162X
VL - 7
SP - 83
EP - 90
JO - Current HIV Research
JF - Current HIV Research
IS - 1
ER -